medigraphic.com
ISSN 0185-3325 (Impreso)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2004, Número 6

<< Anterior Siguiente >>

Salud Mental 2004; 27 (6)


Tratamiento farmacológico de la fase depresiva del trastorno bipolar (depresión bipolar). Segunda parte

Chávez-León E

Idioma: Español
Referencias bibliográficas: 103
Paginas: 8-16
Archivo PDF: 304.35 Kb.


FRAGMENTO

TRATAMIENTO COMBINADO
Es posible que se tenga que utilizar en algunos casos una combinación de diferentes estabilizadores del ánimo. Freeman y Stoll (32) propusieron, después de revisar la seguridad y la eficacia de estos medicamentos, que el carbonato de litio administrado con algún anticonvulsivante, con efecto estabilizador del ánimo, particularmente el valproato, es la combinación más segura y eficaz.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. AKISKAL HW, WALKER P, PUZANTIAN VR, KING D, ROSENTHAL T, DRANON M: Bipolar outcome in the course of depressive illness: Phenomenologic, familial, and pharmacologic predictors. J Affect Disorders, 5:115–128, 1983.

  2. ALTSHULER L, SUPPES T, BLACK D, NOLEN WA, KECK PE y cols.: Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiat, 160:1252-1262, 2003.

  3. AMERICAN PSYCHIATRIC ASSOCIATION: Practice guidelines for treatment of patients with bipolar disorder. Am J Psychiat, 159:1-50, 2002.

  4. ANGST F, STASSEN HH, CLAYTON PJ, ANGST J: Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disorders, 68:167-181, 2002.

  5. ASOCIACION PSIQUIATRICA AMERICANA: DSM- IVTR. Manual Diagnóstico y Estadístico de los Trastornos Mentales. Texto revisado. Masson, Barcelona, 2002.

  6. BALDESSARINI RJ, TONDO L, HENNEN J: Effect of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiat, 60:77– 84, 1999.

  7. BALLENGER JC, POST RM: Carbamazepine in manicdepressive illness: a new treatment. Am J Psychiat, 137:782-790, 1980.

  8. BARON M, GERSHON ES, RUDY V, JONAS WZ, BUCHSBAUM M: Lithium carbonate response in depression. Arch Gen Psychiat, 32:1107-111, 1975.

  9. BAUER MS, RASGON N, GROF P, GYULA L, GLENN T, WHYBROW PC: Mood Patterns in Patients with Bipolar Disorder: Influence of Antidepressants. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  10. BAUER MS, MITCHENER L: What is a “mood stabilizer”? An evidence-based response. Am J Psychiat, 161(1):3-18, 2004.

  11. BOWDEN C, CALABRESE JR, ASHER J: Spectrum of efficacy of lamotrigine in bipolar disorder: overview of double blind placebo- controlled studies. Presentado en el American College of Neuropsychopharmacology, 39th Annual Meeting, San Juan Puerto Rico, diciembre 2000.

  12. BOWDEN C, CALABRESE JR, SACHS G, YATHAM LN, ASGHAR SA y cols.: For the Lamictal 606 Study Group: A placebo- controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiat, 60:392-400, 2003.

  13. CALABRESE JR, BOWDEN CL, McELROY SL: Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiat, 156:1019-1023, 1999.

  14. CALABRESE JR, BOWDEN CL, SACHS GS, ASCHER JA, MONAGHAN E, RUDD GD: A double-blind placebo controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiat, 60:79-88, 1999.

  15. CALABRESE JR, SHELTON MD, BOWDEN CL, RAPPORT DJ, SUPPES T, SHIRLEY ER: Bipolar rapid cycling: Focus on depression as its hallmark. J Clin Psychiat, 62(Supl.14):34–41, 2001.

  16. CALABRESE JR, BOWDEN CL, SACHS G, YATHAM LN, BEHNKE K y cols.: For the Lamictal 605 Study Group: A placebo- controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiat, 64:1013-1024, 2003.

  17. CALABRESE JR, YATHAM L, SUPPES T, MCELROY S, GOLDBERG JF y cols.: Lamotrigine Controls Bipolar Depression Without Destabilizing-controlled Trials. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  18. CITROME L, LEVINE J, ALLINGHAM B: Utilization of valproato: extent of inpatient use in New York State Office of mental health. Psychiatr Q , 69(4):283-300, 1998.

  19. COHN JB, COLLINS G, ASHBROOK E, WERNICKE JF: A comparision of fluoxetina, imipramina and placebo in patients with bipolar depressive disorder. Clin Psychopharmacol, 4:313-322, 1989.

  20. CORYEL W, SCHEFTNER W, KELLER M: The enduring psychosocial consecuences of mania and depression. Am J Psychiat, 150:720-727, 1993.

  21. D’SOUZA R, KEKS N, RICH D, DIAMOND I, GODFERY K: An open randomized control study using a spiritually augmented cognitive behavior therapy for demoralization and treatment adherence in patients with bipolar I depression. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  22. DAVIS LL, KABEL D, PATELN D, CHATOE AD, FOSLIEN-NASH C, GURGUIS GNM: Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull, 32:647–652, 1996.

  23. DENIKOFF KD, SMITH-JACKSON EE, DISNEY ER, ALI SO, LEVERICH GF, POST RM: Comparative prophylactic efficacy of litihium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiat, 58:470–478, 1997.

  24. DUBE S, TOLLEFSON GD, THASE ME, BRIGGS SD, VAN CAMPEN LE y cols.: Onset of action of olanzapine combination in bipolar depression. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  25. DUNNER DL, PATRICK V, FIEVE RR: Rapid cycling manic depressive patients. Compr Psychiat, 18:561–566, 1977.

  26. EL-MALLAKH RS, KARIPPOT A, WELTER M: Antidepressant- induced chronic irritable dysphoria (ACID). V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  27. EVINS EA, NIEREMBERG A, EISNER L, OGUTHA J y cols.: Inositol augmentation of mood stabilizers for bipolar depresión. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  28. FAEDDA GL, BALDESSARINI RJ, SUPPES T, TONDO L y cols.: Pediatric-onset bipolar disorder: a neglected clinical and public health problem. Harv Rev Psychiatry, 3:171-195, 1995.

  29. FENN HH, ROBINSON D, LUBY V, DANGEL C, BUXTON E y cols.: Trends in Pharmacotherapy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiat, 153(5):711-713, 1996.

  30. FINDLING RL, MCNAMARA NK, GRACIOUS BL, YOUNGSTROM EA, STANBREY RJ y cols.: Combination lithium and divalproex sodium in pediatric bipolarity. J Am Acad Child Adolesc Psychiatry, 42(8):895-901, 2003.

  31. FRANK E, SWARTZ HA, KUPFER DJ: Interpersonal and social rythm therapy: Managing the chaos of bipolar disorder. Biol Psychiat, 48:593-604, 2000.

  32. FREEMAN MP, STOLL AL: Mood stabilizer combinations: A review of safety and efficacy. Am J Psychiat, 155:12-21, 1998.

  33. FRYE MA, KETTER TA, KIMBRELL TA: A placebocontrolled study of lamotrigine and gabapentina monotherapy in refractory mood disorders. J Clin Psychopharm, 20:607-614, 2000.

  34. GELLER B: Valproate and polycystic ovaries. J Am Acad Child Adolesc Psychiatry, 37(1):9-10, 1998.

  35. GHAEMI SN, LENOX MS, BALDESSARINI RJ: Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiat, 62:565–569, 2001.

  36. GHAEMI SN, SACHS GS: Long-term risperidone treatment in bipolar disorder: a 6-month follow up. Int J Neuropharmacol, 12:333-338, 1997.

  37. GHAEMI SN: New Strategies for Managing Bipolar Disorder. APA Annual Meeting, San Francisco, 2003.

  38. GHAEMI SN, ROSENQUIST KJ, KO JY, GOODWIN FK, BALDESSARINI RJ: Effects of newer and older antidepressants in bipolar depression. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  39. GOODWIN FK, MURPHY DL, DUNNER DL Y BUNNEY WE Jr: Lithium response in unipolar versus bipolar depression. Am J Psychiat, 129:44-47, 1972.

  40. GOODWIN FK, JAMISON KR: Manic-Depressive Illness. Oxford University Press, Nueva York, 1990.

  41. GOODWIN FK, BOWDEN CL, CALABRESE JR, GRUNZE H, KASPER S y cols.: A pooled analysis of 2 placebo- controlled 18 month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiat, 65:432-441, 2003.

  42. GOODWIN FK, FIREMAN B, SIMON GE, HUNKELER EM, LEE J y cols.: Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA, 290(11):1467-1473, 2003.

  43. GREIL W, KLEINDIENST N: The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol, 14:277-281, 1999.

  44. HERZOG AG, SEIBEL MM, SCHOMER DL, VAITUKAITIS JL, GERSCHWIND N: Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol, 43:341-346, 1986a.

  45. HERZOG AG, SEIBEL MM, SCHOMER DL, VAITUKAITIS JL, GERSCHWIND N: Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch Neurol, 43:347-350, 1986b.

  46. HIMMELHOCH JM, THASE ME, MALLINGER AG, HOUCK P: Tranylcypromine versus imipramina in anergic bipolar depression. Am J Psychiat, 148:910-916, 1991.

  47. HIRSCHFELD RMA: Bipolar spectrum disorder: improving its recognition and diagnosis. J Clin Psychiat, 62(supl 14):5-9, 2001.

  48. IRWIN M, MASAND P: Valproate and polycystic ovaries. J Am Acad Child Adolesc Psychiatry, 37(1):9, 1998.

  49. ISOJARVI JI, LAATIKAINEN TJ, KNIP M, PARKARINEN AJ, JUNTUNEN KT, MYLLYLA VV: Obesity and endocrine disorders in women taking valproato for epilepsy. Ann Neurol, 39(5):579-584, 1996.

  50. JANICAK PG, DAVIS JM, AYD FJ: Advances in the pharmacotherapy of bipolar disorder. Principles Practice Psychopharmacotherapy, 1(3):1–19, 1995.

  51. JOFFE RT, MacQUEEN GM, YOUNG LT: Psychopharmacology for the clinician: What is the best approach to management of acute depression in bipolar disorder? Review Psychiatry Neuroscience, 25(5):516, 2000.

  52. JOFFE RT: How should litihum-induced thyroid dysfunction be managed in patients with bipolar disorder? J Clin Psychiat, 27:392, 2002.

  53. JUDD LL, AKISKAL HS, SCHETTLER PJ, CORYELL W, ENDICOTT J y cols.: A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiat, 60(3):261-269, 2003.

  54. KAAJA E, KAAJA R, HIILESMAA V: Major malformations in offspring of women with epilepsy. Neurology, 60(4):575-579, 2003.

  55. KALOGJERA-SACKELLARES D, SACKELLARES JC: Improvement in depression associated with partial epilepsy in patients treated with lamotrigine. Epilepsy Behav, 3(6):510– 516, 2002.

  56. KESSLER RC, MCGONAGLE KA, ZHAO S, NELSON CB, HUGHES M y cols.: Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United States: Results From the National Comorbidity Survey. Year Book of Psychiatry Applied Mental Health. (7):192, Annual 1995.

  57. KUSUMAKAR V, MCINTYRE R, BINDER C, RICCARDELLI R: Topiramate as adjunctive therapy to mood stabilizers in patients with bipolar I or II disorder. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  58. LATTANZI L, BENEDETTI A, PINI S, MUSETTI L, CASSANO GB: Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  59. MACEDO-SOARES MB, MORENO RA, RIGONATTI SP, LAFER B: Electroconvulsive therapy in treatment resistant bipolar disorder – case report. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  60. MARANGELL LB, YUDOFSKY SC, SILVER JM: Psychopharmacology and electroconvulsive therapy. En: Hales RE, Yudofsky SC, Talbott JA (eds.), The American Psychiatric Press Textbook of Psychiatr y. (3rd ed., pp 1025- 1132). Washington,1999.

  61. McELROY SL, KECK P, POPE HG, HUDSON JI: Valproate in the treatment of rapid- cycling bipolar disorder. J Clin Psychopharm, 8(4):275-279, 1998.

  62. McELROY SL, SUPPES T, KECK P, FRYE MA, DENICOFF KD y cols.: Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiat, 47(12):1025-1033, 2000.

  63. McINTYRE RS, MANZINI DA, MCCANN S, SRINIVASAN J, SAGMAN D, KENNEDY SH: Topiramate versus bupropión SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary singleblind study. Bipolar Disord, 4:207–213, 2002.

  64. MEDINA-MORA ME, BORGES G, LARA-MUÑOZ C, BENJET C, BLANCO JJ y cols.: Prevalencia de trastornos mentales y uso de servicios: Resultados de la Encuesta Nacional de Epidemiología Psiquiátrica en México. Salud Mental, 26(4):1-16, 2003.

  65. MENDELS J: Lithium in the treatment of depression. Am J Psychiat, 133:373-378, 1976.

  66. MESSENHEIMER J, MULLENS EL, GIORGI L, YOUNG F: Safety review of adult clinical trial experience with lamotrigina. Drug Saf, 18:281-296, 1998.

  67. MITCHELL PB, WILHELM K, PARKER G, AUSTIN MP, RUTGERS P, MALHI GS: The clinical features of bipolar depression: A comparison with matched major depressive disorder patients. J Clin Psychiat, 62:212–216, 2001.

  68. MÖLLER HJ, NASRALLAH HA: Treatment of bipolar disorder. J Clin Psychiat, 64:[supl 6], 9-17, 2003.

  69. MUNDO E, WALKER M, CATE T, MACCIARDI F, KENNEDY JL: The role of serotonin Transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiat, 58(6):539-544, 2001.

  70. MUÑOZ RA: Oxcarbazepine for the treatment of bipolar disorder. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  71. MURIALDO G, GALIMBERTI CA, GIANELLI MV, ROLLERO A, POLLERI A y cols.: Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol, 21(1):52-58, 1998.

  72. OSBY U, BRANDT L, CORREIA N, EKBOM A, SPAREN P: Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiat, 58:844-850, 2001.

  73. PAPOLOS DF, GREENBERG R, TRESKER S, FREEMAN K: Antidepressant- induced adverse effects in juvenile- onset bipolar disorder. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  74. PASSMORE MJ, GARNHAM J, DUFFY A, MACDOUGALL M, MUNRO A y cols.: Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord, 5:110-114, 2003.

  75. PAZZAGLIA PJ, POST RM, KETTER TA, CALLAHAN AM, MARANGELL LB, FRYE MA: Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharm, 18:404-413, 1998.

  76. PERRY C: A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiat Scand, 42:1–188, 1996.

  77. PETTY F: GABA and mood disorders: A brief review and hypothesis. J Affect Disorders, 34:275–281, 1995.

  78. POST RM: Mood disorders: Treatment of bipolar disorders. En: Sadock BJ, Sadock VA (eds.) Comprehensive Textbook of Psychiatry, Williams and Wilkins, 1385–1430 Nueva York, 1999.

  79. PRICE LH, HENINGER GR: Lithium in the treatment of mood disorders. New Engl J Med, 331:591–598, 1994.

  80. RUZICKOVA M, ALDA M: Psychopharmacology for the clinician: antidepressants in bipolar depression: when less is more. Rev Psychiatr Neurosci, 27(4):312, 2002.

  81. SACHS GS: Treatment–resistant bipolar depression. Psychiatr Clin North Am, 19:125–236, 1996.

  82. SACHS GS, THASE M: Bipolar disorder therapeutics: Maintenance treatment. Biol Psychiat, 48:573-581, 2000a.

  83. SACHS GS, THASE M: Bipolar depression: Pharmacotherapy and related therapeutic strategies. Biol Psychiat, 48:558-72, 2000b.

  84. SACHS GS, ALTSHULER L, KETTER TA: Divalproex versus Placebo for the Treatment of Bipolar Depression. Presentado en el American College of Neuropsychopharmacology, 40th Annual Meeting, San Juan, diciembre 2001.

  85. SADOCK BJ, SADOCK VA: Synopsis of Psychiatry. Novena edición. Lippincott Williams & Wilkins, Philadelphia, 2003.

  86. SCHATZBERG AF, COLE JO, DEBATTISTA C: Manual of Clinical Psychopharmacology. American Psychiatric Publishing, Inc., Washington, 2003.

  87. SHARMA R, MARKAR HR: Mortality in affective disorder. J Affect Disorders, 31:91-96, 1994.

  88. SOARES JC: Valproate treatment and the risk of hyperandrogesnim and polycystic ovaries. Bipolar Disord, 2:37-41, 2000.

  89. SOLOMON DA, KEITNER GI, MILLER IW: Course of illness and maintenance treatments for patients with bipolar disorders. J Clin Psychiat, 56:5–13, 1995.

  90. SOLOMON DA, KEITNER GI, RYAN CE, MILLER IW: Litihium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: a review. J Clin Psychopharm, 18(1):38-49, 1998.

  91. STOLL AL, SEVERUS WE, FREEMAN MP: Omega three fatty acids in bipolar disorder: a preliminary double-blind, placebo–controlled trial. Arch Gen Psychiat, 56:407–412, 1999.

  92. SUPPES T, WEBB A, PAUL B, CARMODY T, KRAEMERH, RUSH AJ: Clinical outcomes in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiat, 156:1164-1169, 1999.

  93. SWANN AC, BOWDEN CL, MORRIS D, CALABRESE JR, PETTY F, SMALL J: Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiat, 54:37–42, 1997.

  94. TAMADA RS, ISSLER CK, AMARAL JAMS, LAFER B: Outcome of antidepressant- induced mania: a controlled study. V Conferencia Internacional sobre Trastorno Bipolar. Sección de posters. Pittsburgh, 2003.

  95. THASE MF, MALLINGER AG, MCKNIGHT D, HIMMELHOCH JM: Treatment of imipramine- resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiat, 149:195-198, 1992.

  96. THIES-FLECHTNER K, MULLER-OERLINGHAUSEN B, SELBERT W: Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Pharmacopsychiatry, 29:103-107, 1996.

  97. TOHEN M, ANGST J: Epidemiology of bipolar disorder. En: Tsuang MT, Tohen M (eds.). Psychiatric Epidemiology. New York: Willey–Liss, 427- 444, Nueva York, 2002.

  98. TOHEN M, VIETA E, CALABRESE J, KETTER TA, SACHS G y cols.: Efficacy of olanzapine and olanzapine-fluoxetina combination in the treatment of bipolar I depression. Arch Gen Psychiat, 60:1079-1088, 2003.

  99. TOHEN M, VIETA E, KETTER T: Olanzapine in the treatment of bipolar depression. Int J Neuropharmacol, 5 (supl. 1): S109, 2002.

  100. VIETA E, TORRENT C, GARCIA- RIBAS G, GILBERT A, GARCIA- PARÉS y cols.: Use of topiramate in treatmentresistant bipolar spectrum disorders. J Clin Psychopharm, 22(4):431-435, 2002.

  101. WEISSMAN MM, PRUSOFF BA, MERIKANGAS KR: Is delusional depression related to bipolar disorder? Am J Psychiat, 141:882–892, 1984.

  102. YOUNG LT, ROBB JC, PATELLIS-SIOTIS I, MACDONALD C, JOFFE RT: Acute treatment of bipolar depression with gabapentin. Biol Psychiat, 42:851-853, 1997.

  103. YOUNG LT, JOFFE RT, ROBB JC, MACQUEEN GM, MARRIOTT M y cols.: Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiat, 157:124-126, 2000.




2020     |     www.medigraphic.com